Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia

Kobbe, Guido; Fenk, Roland; Neumann, Frank; Bernhardt, A.; Steidl, Ulrich; Kondakci, Mustafa; Graef, Thorsten; Aivado, Manuel; Vaupel, Matthias; Huenerlituerkoglu, Ali-Nuri; Kronenwett, Ralf; Pape, Hans-Christian; Hildebrand, B.; Germing, Ulrich; Haas, Rainer

doi:10.1080/14653240410005375

Cited by 12 publications

(9 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, prophylactic DLI was administered after full intensity T-cell depleted allogeneic transplants with promising results by Kobbe et al . Seventy-four percent of 14 patients with AML/MDS showed disease-free survival at one year, with minimal GVHD [43]. Of the 6 AML/MDS patients who died, three had relapsed.…”

Section: Relapse Management and Maintenance Strategies After Allo-hctmentioning

confidence: 99%

Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Mawad

Lionberger

Pagel

2013

Curr Hematol Malig Rep

View full text Add to dashboard Cite

The incidence of acute myeloid leukemia (AML) is expected to increase in conjunction with our ageing population. Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. These efforts involve every step of AML diagnostics and therapy, including the intricate processes of conditioning, graft manipulation and immunomodulation. The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant.

show abstract

Section: Relapse Management and Maintenance Strategies After Allo-hctmentioning

confidence: 99%

Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Mawad

Lionberger

Pagel

2013

Curr Hematol Malig Rep

View full text Add to dashboard Cite

show abstract

“…This is due to the fact that the removal of T-lymphocytes from allogeneic grafts prevents both acute and chronic GvHD (Ho and SoiVer 2001;Lee et al 2002) on the one hand, but on the other hand it is associated with higher rates of graft failure and poorer outcome by relapse of underlying malignancies (Urbano-Ispizua et al 2002;Bornhauser et al 2002;Kobbe et al 2004). PuriWcation of CD34+ donor cells is another indirect way to deplete T-cells in the graft (Lang et al 2003;Butt et al 2003).…”

Section: Discussionmentioning

confidence: 97%

“…The transplantation of allogeneic CD34+ selected PBPC followed by early T-cell add backs could be a strategy to prevent relapses (Kobbe et al 2004). However, CellPro manipulated grafts contained about 5 £ 10 5 /kg body weight T-cells.…”

Section: Discussionmentioning

confidence: 99%

Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors

Kopp

Wirths

Faul

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…However, side effects of intensive MA conditioning have limited its application to younger patients in excellent clinical condition. Recent improvements, including better donor selection [5], improved management of infectious complications [2,14], development of reduced-intensity conditioning regimens [15][16][17][18] and less toxic methods of GvHD prophylaxis [19] have generated considerable interest in extending the use of allogeneic transplantation to older and less fit patients [1][2][3]. The intention of our retrospective analysis was to determine the importance of clinical parameters associated with a favourable outcome.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing myeloablative or non‐myeloablative allogeneic blood stem cell transplantation

Graef

Vaupel

Fenk

et al. 2007

Hematological Oncology

View full text Add to dashboard Cite

In this uni-centre retrospective study, we studied 120 adults with acute myeloid leukaemia (AML) (n = 88) and myelodysplastic syndrome (MDS) (n = 32) who received first allogeneic HSCT to determine prognostic factors which are correlated with the outcome after myeloablative (MA) or non-myeloablative (non-MA) allogeneic HSCT. The median age of our cohort was 44 years. Fifty-nine per cent of the patients were transplanted in complete remission (CR) and 41% were in relapse or refractory to induction or salvage therapy. A total of 97 patients received a MA regimen and 23 were treated with a non-MA regimen. The prognostic impact for several parameters was assessed by univariate and by multivariate analyses using the Cox regression model. Three-year probabilities of non-relapse mortality (34 vs. 54%; p = 0.9) did not differ in the MA and non-MA groups, but differences were observed in the disease-free survival (DFS) (43 vs. 17%; p = 0.1) and the relapse rate (RR) (29 vs. 62%; p = 0.01). Independently from the regimen, in uni- and multivariate analysis, survival was best in those patients who were transplanted in CR and experienced cGvHD. Interestingly, outcome of patients with complex cytogenetic aberrations was identical to that of better prognostic subgroups. In this study, the clinical benefit of a lower toxicity regimen was offset by higher RR resulting in inferior results in the non-MA group, especially when no CR was achieved by prior induction or salvage therapy.

show abstract

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia

Cited by 12 publications

References 59 publications

Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors

Prognostic factors for patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing myeloablative or non‐myeloablative allogeneic blood stem cell transplantation

Contact Info

Product

Resources

About